Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

Feed excerpt — reported by MarketWatch

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at MarketWatch →

View MAP Context →